Home › Acute Biphenotypic Leukemia › New Jersey
Acute Biphenotypic Leukemia clinical trials in New Jersey
6 studies for Acute Biphenotypic Leukemia are looking for participants at sites in New Jersey.
Cities in New Jersey
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Hackensack University Medical Center, Hackensack
- Morristown Medical Center, Morristown
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick
- and 1 more
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Hackensack University Medical Center, Hackensack
- Morristown Medical Center, Morristown
- Jersey Shore Medical Center, Neptune City
- and 4 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Hackensack University Medical Center, Hackensack
- Morristown Medical Center, Morristown
- Jersey Shore Medical Center, Neptune City
- and 3 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443A Study of Revumenib and Mezigdomide in People With Leukemia
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Jun 22, 2026 · NCT07356154From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.